Clinical Observation of Medroxyprogesterone Combined with TC Regimen in the Treatment of Endometrial Cancer
Objective To investigate the clinical efficacy of medroxyprogesterone combined with TC regimen(paclitaxel+carboplatin)in the treatment of endometrial cancer.Methods A total of 110 patients with endometrial cancer admitted to the Obstetrics and Gynecology Department of Rongxian People´s Hospital from January 2019 to June 2023 were selected and divided into the observation group(60 cases)and the control group(50 cases)according to different treatment regimens.The patients in the two groups received intravenous drip of Paclitaxel Injection and Carboplatin Injection on the first day of the cycle,and both groups were treated for three cycles with 21 d per cycle;on this basis,the patients in the observation group were treated with oral Medroxyprogesterone Acetate Tablets for continuous nine weeks.Results The total effective rate in the observation group was 85.00%,which was significantly higher than 66.00%in the control group(P<0.05).After treatment,the vascular endothelial growth factor(VEGF),matrix metalloproteinase-9(MMP-9),tumor markers[carbohydrate antigen 125(CA125),carbohydrate antigen 199(CA199),human epididymis protein 4(HE4),carcinoembryonic antigen(CEA)]levels in the two groups significantly decreased;the scores of various items of quality of life(physiological condition,social condition,emotional condition,functional condition)significantly increased;and the above indexes in the observation group were significantly better(P<0.05).The incidence of adverse reactions in the observation group was similar to that in the control group(8.33%vs.12.00%,P>0.05).Conclusion Medroxyprogesterone combined with TC regimen can significantly decrease the serum VEGF,MMP-9 and relevant tumor marker levels in patients with endometrial cancer,and improve their quality of life.
medroxyprogesteroneTC regimenendometrial cancerclinical efficacyvascular endothelial growth factormatrix metalloproteinase-9tumor markerquality of life
万方数据
维普
